Program
Embibatinib
Also written as “HS-10382”, “MK-4208” and “TERN-701”.
In Hansoh Pharmaceutical Group's pipeline, BCR-ABL (STAMP)
. Its studies are mostly in Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Leukemia, Myeloid, Chronic-Phase, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Group | 44 open or running | phase 3since Oct 12, 2026 | May 6, 2022 | Feb 2027phase 1 · NCT07933224 |
| Merck | 31 open or running | phase 2since Nov 8, 2023 | Nov 8, 2023 | Nov 30, 2029phase 2 · NCT06163430 |
- Named in Hansoh Pharmaceutical Group’s own pipeline as
HS-10382 (STAMP, Terns's TERN-701)
, phase 1, as of Aug 26, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 6, 2022First study: phase 1 study in Leukemia, Myeloid, Chronic-PhaseNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT05367700 · 108 planned · China
- Nov 8, 2023Merck's first study: phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNew to MerckMerck · NCT06163430 · 330 planned · United States, Australia, France and more
- Jul 19, 2024Phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveHansoh Pharmaceutical Group · NCT06530810 · 100 planned
- Sep 18, 20262 phase 1 studies in HealthyMerck · NCT07839000, NCT07838987
- Oct 12, 2026Phase 3 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositivePhase 3 reachedHansoh Pharmaceutical Group · NCT07885293 · 408 planned · China
- Nov 2, 2026Phase 1 study in Healthy VolunteersHansoh Pharmaceutical Group · NCT07933224 · 32 planned · China
Ahead
- Feb 2027Primary completion: phase 1 study in Healthy VolunteersHansoh Pharmaceutical Group · NCT07933224
- Jul 2029Primary completion: phase 3 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveHansoh Pharmaceutical Group · NCT07885293
- Nov 30, 2029Primary completion: phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveMerck · NCT06163430
TargetBeta
“BCR-ABL (STAMP)”the company's pipeline, read by Claude · source
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| imatinibrule | Novartis | phase 4 | 70 |
| nilotinibrule | Novartis | phase 4 | 57 |
| asciminibrule | Novartis | phase 4 | 16 |
| olverembatinibrule | Ascentage Pharma Group International | phase 3 | 10 |
| TQB3911 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07933224Healthy Volunteers · China | 1 | Not yet recruiting | Hansoh Pharmaceutical Group | Feb 2027 | 32 |
| NCT07885293Leukemia, Myelogenous, Chronic, BCR-ABL Positive · China | 3 | Not yet recruiting | Hansoh Pharmaceutical Group | Jul 2029 | 408 |
| NCT07839000Healthy · United States | 1 | Completed | Merck | Apr 3, 2026 | 8 |
| NCT07838987Healthy · United States | 1 | Completed | Merck | Jun 30, 2026 | 196 |
| NCT06530810Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | Not yet recruiting | Hansoh Pharmaceutical Group | May 8, 2026 | 100 |
| NCT06163430Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Australia, France and more | 2 | Recruiting | Merck | Nov 30, 2029 | 330 |
| NCT05367700Leukemia, Myeloid, Chronic-Phase · China | 1 | Recruiting | Hansoh Pharmaceutical Group | Dec 30, 2024 | 108 |
How it is read
Names in the registry
- “HS-10382”, 2 entries
- “Embibatinib”, 1 entry
- “MK-4208”, 1 entry
- “TERN-701”, 1 entry
- “HS-10382+Flumatinib”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive, 3 studies
- Leukemia, Myeloid, Chronic-Phase, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.